Provenge Off-Label Use Is Key CMS Concern In NCA, Dendreon Says
Executive Summary
In its ongoing national coverage analysis of Dendreon's Provenge (sipuleucel-T), the Centers for Medicare and Medicaid Services is taking a close look at Medicare coverage for off-label use of the novel prostate cancer vaccine, according to the company
You may also be interested in...
Provenge Data Not Supportive Of Off-Label Uses, MEDCAC Finds
The existing clinical data on Dendreon's prostate cancer vaccine Provenge cannot be "generalizable" to off label uses, most members of the Medicare Evidence Development and Coverage Advisory Committee agreed at a Nov. 17 meeting.
Parallel Review Could Deter NCD, Medicare Exec Says; Provenge A Case In Point?
Overlapping FDA product approval and Medicare coverage reviews could help biopharmaceutical firms avoid a later Medicare national coverage determination for a new therapy, CMS Coverage and Analysis Group Director Louis Jacques suggested during a webinar sponsored by Avalere Health Sept. 30.
Parallel Review Could Deter NCD, Medicare Exec Says; Provenge A Case In Point?
Overlapping FDA product approval and Medicare coverage reviews could help biopharmaceutical firms avoid a later Medicare national coverage determination for a new therapy, CMS Coverage and Analysis Group Director Louis Jacques suggested during a webinar sponsored by Avalere Health Sept. 30.